Nanoligent

Nanoligent was stablished on March 2017 by professors Dr. A. Villaverde and Dra. E. Vázquez from the Nanobiotecnology Group of the UAB,.Nanoligent is a biotechnology startup with a mission to revolutionize cancer treatment through targeted nanomedicine. Their innovative platform focuses on delivering therapeutic agents directly to cancer cells, enhancing efficacy while reducing the harmful side effects associated with traditional chemotherapy. “Our goal is to change the way cancer is treated by focusing therapies precisely on the affected cells,” says Dr. Schwartz. Nanoligent’s technology uses antibody-based nanoparticles to ensure that drugs are delivered only to the cancerous tissue, sparing healthy cells. This targeted approach improves patient outcomes and minimizes toxicity. With multiple preclinical trials showing promise, Nanoligent is positioned to make a transformative impact in oncology, providing new hope for patients with aggressive and hard-to-treat cancers.

View website
Scroll to top